Tag: Psoriasis
Infection Risk Lower With Certain Psoriasis Treatments
Risk for serious infection reduced for new users of apremilast, etanercept, ustekinumab versus methotrexate
Higher Risk for Mental Disorders Seen in Patients With Psoriasis
Time to onset found to be two to three months for anxiety disorders and other conditions
Psoriasis Symptoms, Quality of Life Tied to Disease Severity
Findings show alignment of patient-reported symptoms, clinician assessment tools
DLQI With ‘Not Relevant’ Answers May Underrate Psoriasis Severity
Objective, subjective disease severity worse for those responding 'not relevant' versus 'not at all'
Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
Drug survival rates higher than for adalimumab, etanercept for all treatment and psoriasis types
Age, Race Impact Atherosclerotic Risk With Psoriasis
Increased risk for atherosclerotic CVD seen at younger age in African-Americans with psoriasis
Guideline Covers Extracutaneous Manifestations of Psoriasis
Second guideline presents evidence for different biologic agents, including adverse events
Psoriasis Tx Linked to Drop in Noncalcified Coronary Plaque
Noncalcified plaque burden and necrotic core reduced in association with biologic therapy
Methotrexate Well Tolerated, Effective for Psoriasis in Chinese
Greater therapeutic response, fewer adverse events seen in those without psoriatic arthritis
Hypertension With Psoriasis Tied to More Cardiac Interventions
In patients with hypertension, psoriasis linked to increased risk for cardiovascular procedures, surgeries
